Table 2

Comparison of NAFLD concomitant rates under different glucose metabolism status between South and North group

No of NAFLDNAFLD prevalence (%)OR (95% CI)
UnadjustedModel 1Model 2Model 3
All participants (n=2420)
 South54535.951 (Ref)1 (Ref)1 (Ref)1 (Ref)
 North50555.862.25 (1.91 to 2.67)2.23 (1.87 to 2.68)3.56 (2.84–4.47)3.09 (2.45–3.90)
 P value<0.001<0.001<0.001<0.001
NGT (n=750)
 South7516.231 (Ref)1 (Ref)1 (Ref)1 (Ref)
 North10034.722.74 (1.94 to 3.89)3.05 (2.06 to 4.55)4.45 (2.79–7.19)4.15 (2.52–6.95)
 P value<0.001<0.001<0.001<0.001
IGR (n=425)
 South9634.661 (Ref)1 (Ref)1 (Ref)1 (Ref)
 North9161.493.01 (2.00 to 4.57)2.90 (1.85 to 4.60)5.54 (3.17–9.94)4.45 (2.49–8.17)
 P value<0.001<0.001<0.001<0.001
T2DM (n=1245)
 South37448.131 (Ref)1 (Ref)1 (Ref)1 (Ref)
 North31467.092.20 (1.73 to 2.79)1.96 (1.53 to 2.53)2.91 (2.14–3.97)2.54 (1.86–3.50)
 P value<0.001<0.001<0.001<0.001
  • Multivariate logistic regression models were gradually adjusted for: Model 1 was adjusted for age, gender, alcohol drinking and cigarette smoking. Model 2 was adjusted for BMI, WC, FBG, SBP, TG, TC, LDL-c, HDL-c, UA and statins treatment in addition to factors included in model 1. Model 3 was adjusted for ALT, AST, GGT in addition to factors included in model 2.

  • ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FBG, fasting blood glucose; GGT, gamma-glutamyl transferase; HDL-c, high-density lipoprotein cholesterol; IGR, impaired glucose regulation; LDL-c, low-density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease; NGT, normal glucose tolerance; SBP, systolic blood pressure; TC, total cholesterol; T2DM, type 2 diabetes mellitus; TG, triglyceride; UA, uric acid; WC, waist circumference.